Gepride 1 Tablet contains Glimepiride 1 mg, an oral antihyperglycemic agent belonging to the sulfonylurea class, indicated for the management of type 2 diabetes mellitus. It functions primarily by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with insufficient endogenous insulin secretion. Gepride 1 is typically prescribed as an adjunct to diet and exercise to achieve optimal blood glucose levels. The medication is particularly beneficial for patients who have not attained adequate glycemic control with lifestyle modifications alone. Glimepiride exhibits a rapid onset of action and a prolonged duration, allowing for once-daily dosing, which enhances patient compliance. Prior to initiation, renal and hepatic function should be assessed, as dose adjustments may be necessary in cases of impairment. Common adverse effects include hypoglycemia, weight gain, and gastrointestinal disturbances. Patients should be counseled on recognizing symptoms of hypoglycemia and advised to maintain regular meal patterns to minimize risk. Gepride 1 should be used cautiously in combination with other antidiabetic agents to prevent additive hypoglycemic effects. Regular monitoring of blood glucose and HbA1c levels is recommended to evaluate therapeutic efficacy and adjust dosing accordingly. This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas.